No Data
Express News | National Medical Products Administration: Deploys pilot work on segmented production reform of biological products.
Sudden Movement Spotlight | Biomedical Class B shares rose in the afternoon, LKYG-B up 30%, institutions bullish on sector further recovery space
Biomedical Class B shares rose in the afternoon, as of the time of publication, Lai Kai Medicine-B rose by 27.88%, to 7.89 Hong Kong dollars; YimingAngke-B rose by 17.91%, to 5.86 Hong Kong dollars; Yasheng Medicine-B rose by 5.74%, to 46.95 Hong Kong dollars.
Who's buying? The A-share market is closed, but the Hong Kong stock market is still going strong! There's a big shift in foreign capital underway.
According to the latest report published by Goldman Sachs, after the People's Bank of China announced easing measures and the September Political Bureau meeting, mainland consumer stocks rebounded strongly by an average of about 32% in the past week.
MABPHARM-B: 2024 Interim Report
Express News | Hong Kong stock CRO concept stocks soared at the close, what happened?
Performance: Meibo Pharmaceuticals (02181.HK) narrowed its mid-year loss to 97.57 million RMB.
Maibo Pharmaceutical - B (02181.HK) announced its interim performance for the six months ending in June, with revenue of 0.108 billion RMB (the same below), an increase of 146.4% year-on-year. The loss narrowed from 99.999 million yuan in the same period last year to 97.57 million yuan, with a loss per share of 2 fen. No interim dividend will be paid.
No Data
No Data